Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $15.08 which represents a decrease of $-0.01 or -0.07% from the prior close of $15.09. The stock opened at $15.46 and touched a low of $14.9 ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TXG stock, giving a Buy rating on January 13.Stay Ahead of the ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.98 which represents a decrease of $-0.46 or -2.98% from the prior close of $15.44. The stock opened at $16.11 and touched a low of ...

Genomics is innovating in spatial technologies but faces hurdles. Discover why TXG stock’s price/cashflow ratio and ...

Stifel Nicolaus analyst Daniel Arias has maintained their bullish stance on TXG stock, giving a Buy rating yesterday.Stay Ahead of the ...

10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript Bruker Non-GAAP EPS of $0.53 beats by $0.07, revenue of $721.7M misses by $7.34M Bruker Q1 2024 Earnings Preview ...

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:TXG), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes ...

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...